Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of bleximenib + venetoclax + azacitidine versus placebo + venetoclax + azacitidine in newly diagnosed AML with KMT2A rearrangement or NPM1 mutation unfit for intensive chemotherapy
MOH_2025-02-16_013915Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Bleximenib + venetoclax + azacitidine with Placebo + venetoclax + azacitidine (2 arms). Started Jan 2025; status: recruiting.
02
Drugs
bleximenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2025-02-16_013915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013915.